Dawki pośrednie rosuwastatyn w praktyce klinicznej — od teorii, przez EBM, do wskazówek terapeutycznych

Content Provider	Semantic Scholar
Author	Filipiak, Krzysztof Jerzy Walczewski, Michał
Copyright Year	2015
Abstract	Intermediate doses of statin are available on the pharmaceutic market, including the intermediate doses of the most potent one — rosuvastatin (daily doses 15 mg and 30 mg). In the ROSU-PATH trial population of about 500 high cardiovascular risk patients receiving statin therapy in primary and secondary prevention was divided in 2 groups according to drug titration scheme. First group of patients was treated with standard titration scheme 10 mg–20 mg–40 mg. In the second group, alternative scheme 15 mg–30 mg–40 mg was used. All patients underwent medical examination at weeks 0, 4, 8 and 12. Standard titration group obtained lower reduction in total cholesterol and LDL-cholesterol as well as lower increase in HDL-cholesterol. This article describes intermediate doses of statins in the context of current therapeutic indications and evidence-based medicine (EBM) data concerning use of statins in everyday practice. Intermediate doses of statins should acquire an important role in modern clinical practice and may lead to implementation of a new, patient-individualized statin therapy model. Interim results of the ROSU-PATH trial investigating alternative titration scheme (“15–30 scheme”) indicate growing need for a wider use of this form of therapy.
Starting Page	8
Ending Page	14
Page Count	7
File Format	PDF HTM / HTML
Volume Number	12
Alternate Webpage(s)	https://journals.viamedica.pl/choroby_serca_i_naczyn/article/download/41402/28331
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article